Gait changes with anti-dementia drugs: A prospective, open-label study combining single and dual task assessments in patients with Alzheimer's disease

Drugs and Aging

Volumn 31, Issue 5, 2014, Pages 363-372

  Beauchet, Olivier ^a   Launay, Cyrille P ^a   Allali, Gilles ^b   Herrmann, François R ^b   Annweiler, Cedric ^a,c  

^a ANGERS UNIVERSITY HOSPITAL   (France)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; VASODILATOR AGENT;

AGED; ALZHEIMER DISEASE; ANALYZER; ARTICLE; BODY MASS; DOUBLE DISSOCIATION; DSM-IV; FEMALE; FOLLOW UP; GAIT; GAITRITE SYSTEM; GERIATRIC DEPRESSION SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ETHICS; NERVOUS SYSTEM PARAMETERS; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUASI EXPERIMENTAL STUDY; WALKING; WALKING SPEED; CLINICAL TRIAL; DRUG EFFECTS; PATHOPHYSIOLOGY; VERY ELDERLY;

AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; GAIT; HUMANS; MALE; PROSPECTIVE STUDIES;

EID: 84900790693     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-014-0175-3     Document Type: Article

References (35)

1. Montero-Odasso M, Verghese J, Beauchet O, Hausdorff JM. Gait and cognition: a complementary approach to understanding brain function and the risk of falling. J Am Geriatr Soc. 2012;60:2127-36.
2. Beauchet O, Allali G, Berrut G, Hommet C, Dubost V, Assal F. Gait analysis in demented subjects: interests and perspectives. Neuropsychiatr Dis Treat. 2008;4:155-60.
3. Allan LM, Ballard CG, Burn DJ, Kenny RA. Prevalence and severity of gait disorders in Alzheimer's and non-Alzheimer's dementias. J Am Geriatr Soc. 2005;53:1681-7.
4. Beauchet O, Allali G, Poujol L, Barthelemy JC, Roche F, Annweiler C. Decrease in gait variability while counting backward: a marker of "magnet effect"? J Neural Transm. 2010;117:1171-6.
5. Allali G, Dubois B, Assal F, Lallart E, de Souza LC, Bertoux M, Annweiler C, Herrmann FR, Levy R, Beauchet O. Frontotemporal dementia: pathology of gait? Mov Disord. 2010;25:731-7.
6. Beauchet O, Allali G, Annweiler C, Bridenbaugh S, Assal F, Kressig RW, Herrmann FR. Gait variability among healthy adults: low and high stride-to-stride variability are both a reflection of gait stability. Gerontology. 2009;55:702-6.
7. Allali G, Kressig RW, Assal F, Herrmann FR, Dubost V, Beauchet O. Changes in gait while backward counting in demented older adults with frontal lobe dysfunction. Gait Posture. 2007;26:572-6.
8. Verghese J, Wang C, Lipton RB, Holtzer R. Motoric cognitive risk syndrome and the risk of dementia. J Gerontol A Biol Sci Med Sci. 2013;68:412-8.
9. Beauchet O, Allali G, Launay C, Herrmann FR, Annweiler C. Gait variability at fast-pace walking speed: a biomarker of mild cognitive impairment? J Nutr Health Aging. 2013;17:235-9.
10. Beauchet O, Allali G, Thiery S, Gautier J, Fantino B, Annweiler C. Association between high variability of gait speed and mild cognitive impairment: a cross-sectional pilot study. J Am Geriatr Soc. 2011;59:1973-4.
11. Montero-Odasso M, Wells J, Borrie M. Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls. J Am Geriatr Soc. 2009;57:359-60.
12. Assal F, Allali G, Kressig RW, Herrmann FR, Beauchet O. Galantamine improves gait performance in patients with Alzheimer's disease. J Am Geriatr Soc. 2008;56:946-7.
13. Beauchet O, Allali G, Launay C, Fantino B, Annweiler C. Does memantine improve the gait of individuals with Alzheimer's disease? J Am Geriatr Soc. 2011;59:2181-2.
14. Beauchet O, Launay C, Allali G, Watfa G, Gallouj K, Herrmann F, Annweiler C. Anti-dementia drugs and changes in gait: a prepost quasi-experimental pilot study. BMC Neurol. 2013;13:184.
15. Beauchet O, Annweiler C, Dubost V, Allali G, Kressig RW, Bridenbaugh S, Berrut G, Assal F, Herrmann FR. Stops walking when talking: a predictor of falls in older adults? Eur J Neurol. 2009;16:786-95.
16. Ebersbach G, Baas H, Csoti I, Müngersdorf M, Deuschl G. Scales in Parkinson's disease. J Neurol. 2006;253:iv32-5.
17. Shah A, Herbert R, Lewis S, Mahendran R, Platt J, Bhattacharyya B. Screening for depression among acutely ill geriatric inpatients with a short Geriatric Depression Scale. Age Ageing. 1997;26:217-21.
18. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-44.
19. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
20. Kressig RW, Beauchet O. Guidelines for clinical applications of spatio-temporal gait analysis in older adults. Aging Clin Exp Res. 2006;18:174-6.
21. McKeage K. Memantine: a review of its use in moderate to severe Alzheimer's disease. CNS Drugs. 2009;23:881-97.
22. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005;3:CD003154.
23. Seeman P, Caruso C, Lasaga M. Memantine agonist action at dopamine D2High receptors. Synapse. 2008;62:149-53.
24. Parsons CG, Stöffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology. 2007;53:699-723.
25. Tsuno N. Donepezil in the treatment of patients with Alzheimer's disease. Expert Rev Neurother. 2009;9:591-8.
26. Onor ML, Trevisiol M, Aguglia E. Rivastigmine in the treatment of Alzheimer's disease: an update. Clin Interv Aging. 2007;2:17-32.
27. Newell KM, Corcos DM. Issues in variability and motor control. In: Newell KM, Corcos DM, editors. Variability and motor control. Champaign: Human Kinetics; 1993. p. 1-12.
28. Hausdorff JM, Rios DA, Eldelberg HK. Gait variability and fall risk in community-living older adults: a 1-year prospective study. Arch Phys Med Rehabil. 2001;82:1050-6.
29. Maki BE. Gait changes in older adults: predictors of falls or indicators of fear? J Am Geriatr Soc. 1997;45:313-20.
30. Montero-Odasso M, Schapira M, Soriano ER, Varela M, Kaplan R, Camera LA, Mayorga LM. Gait velocity as a single predictor of adverse events in healthy seniors aged 75 years and older. J Gerontol A Biol Sci Med Sci. 2005;60:1304-9.
31. Montero-Odasso M, Schapira M, Varela C, Pitteri C, Soriano ER, Kaplan R, Camera LA, Mayorga LM. Gait velocity in senior people. An easy test for detecting mobility impairment in community elderly. J Nutr Health Aging. 2004;8:340-3.
32. Lan TY, Deeg DJ, Guralnik JM, Melzer D. Responsiveness of the index of mobility limitation: comparison with gait speed alone in the longitudinal aging study Amsterdam. J Gerontol A Biol Sci Med Sci. 2003;58:721-7.
33. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141:1356-64.
34. Montero-Odasso M, Wells JL, Borrie MJ, Speechley M. Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial. BMC Neurol. 2009;9:42.
35. Annweiler C, Fantino B, Parot-Schinkel E, Thiery S, Gautier J, Beauchet O. Alzheimer's disease-input of vitamin D with mE-mantine assay (AD-IDEA trial): study protocol for a randomized controlled trial. Trials. 2011;12:230.